| Ytd | -70.25% | |
| 1y | -69.03% |
| Open | 1.06 | Prev Close | 1.06 | Low | 1.05 | High | 1.15 | Mkt Cap | 134.05M |
| Vol | 1.58M | Avg Vol | 1.44M | EPS | -0.58 | P/E | N/A | Forward P/E | -1.36 |
| Beta | 1.60 | Short Ratio | 6.98 | Inst. Own | 61.60% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-10 | 50-d Avg | 1.15 | 200-d Avg | 2.84 | 1yr Est | 8.40 |
ADCT News
LAUSANNE, Switzerland, Sept. 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today announce
Guggenheim analyst Michael Schmidt maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers t
ADC Therapeutics NYSE: ADCT reported second-quarter 2026 net product revenue of $18.6 million for ZY
ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call Transcript
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.11 per share versus the Zacks Consen
On Thursday, ADC Therapeutics (NYSE:ADCT) discussed second-quarter financial results during its earn
ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.11) per share which beat the analyst c
Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 millio
LAUSANNE, Switzerland, Aug. 6, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-s
Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refin
LAUSANNE, Switzerland, July 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-s
100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamab Full data
NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
Planned ~17% workforce reduction expected to generate annualized estimated savings of approximately
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
NEW YORK, June 18, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
Top Wall Street analysts changed outlook on top names. ADCT downgraded See analysts' views.
U.S. stock futures down on tech profit-taking and weak guidance, ADC Therapeutics shares plunge 50.6
U.S. stock futures down on tech profit-taking and weak guidance, ADC Therapeutics shares plunge 50.6
ADC Therapeutics stock plunges 53% after-hours as investors focus on safety concerns in a phase III
ADC Therapeutics shares slumped nearly 53% in premarket trading on Thursday after a late-stage study
Shares of PVH fell 21.42% in pre-market trading even after strong Q1. Gainers include CXApp, TaoWeav
ADC Therapeutics SA (ADCT) Discusses Phase III LOTIS-5 Trial Results and Next Steps in DLBCL Transcr
Company to host conference call today at 4:30 p.m. EDT LAUSANNE, Switzerland, June 3, 2026 /PRNewswi
U.S. stocks were mixed, with the Dow Jones index surging more than 100 points on Wednesday.
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarte
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings
During the session on Thursday, 461 stocks hit new 52-week lows.
During Tuesday's session, 275 companies made new 52-week lows.
Monday's session saw 175 companies set new 52-week lows.
On Wednesday, 179 companies reached new 52-week lows.